Halozyme Therapeutics

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell HALO and other ETFs, options, and stocks.

About HALO

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence.

CEO

Helen I. Torley

CEOHelen I. Torley

Employees

423

Employees423

Headquarters

San Diego, California

HeadquartersSan Diego, California

Founded

1998

Founded1998

Employees

423

Employees423

HALO Key Statistics

Market cap

12.81B

Market cap12.81B

Price-Earnings ratio

34.03

Price-Earnings ratio34.03

Dividend yield

—

Dividend yield—

Average volume

3.07M

Average volume3.07M

High today

$115.24

High today$115.24

Low today

$112.10

Low today$112.10

Open price

$113.34

Open price$113.34

Volume

2.24M

Volume2.24M

52 Week high

$116.85

52 Week high$116.85

52 Week low

$61.23

52 Week low$61.23

Stock Snapshot

Halozyme Therapeutics(HALO) stock is priced at $113.15, giving the company a market capitalization of 12.81B. It carries a P/E multiple of 34.03.

During the trading session on 2026-09-28, Halozyme Therapeutics(HALO) shares reached a daily high of $115.24 and a low of $112.10. At a current price of $113.15, the stock is +0.9% higher than the low and still -1.8% under the high.

Trading activity shows a volume of 2.24M, compared to an average daily volume of 3.07M.

Over the past 52 weeks, Halozyme Therapeutics(HALO) stock has traded between a high of $116.85 and a low of $61.23.

HALO News

Nasdaq 7h

August 2027 Options Now Available For Halozyme Therapeutics

Investors in Halozyme Therapeutics Inc (Symbol: HALO) saw new options become available today, for the August 2027 expiration. One of the key data points that go...

Simply Wall St 4d

Halozyme Therapeutics Closes A US$1.3b Note Offering, Is The Upside Already Priced In?

Advertisement Convertible notes offering reframes the Halozyme Therapeutics funding story Halozyme Therapeutics (HALO) has just closed a US$1.3b convertible n...

TipRanks 6d

Halozyme Raises $1.5 Billion via Convertible Notes Offering

An update from Halozyme ( (HALO) ) is now available. On September 22, 2026, Halozyme Therapeutics completed a $1.5 billion private offering of 1.50% Convertibl...

Analyst ratings

73%

of 11 ratings

Buy

72.7%

Hold

18.2%

Sell

9.1%

People also own

Based on the portfolios of people who own HALO. This list is generated using Robinhood data, and it’s not a recommendation.

Kratos Defense & Security…

Palo Alto Networks

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.